Variables | Cases (n=637) | Controls (n=467) | t/X2 | p value |
---|---|---|---|---|
Age (years) | 47.52±10.61 | 44.94 ±13.63 | − 3.392 | 0.001 |
Sex | ||||
 Female (%) | 156 (24.5) | 274 (58.7) | 132.406 | <0.001 |
 Male (%) | 481 (75.5) | 193 (41.3) | ||
Years of education | 9.30±6.81 | 9.66±5.33 | 0.955 | 0.340 |
Body mass index | 24.45±4.00 | 25.14±4.18 | 2.538 | 0.011 |
Age of onset (years) | 23.20±5.16 | – | – | – |
Duration of illness (years) | 24.43 ± 10.52 | – | – | – |
Mean daily dose (mg/day) (chlorpromazine equivalents) | 391.72 ± 181.22 | – | – | – |
PANSS total score | 60.81 ± 14.91 | – | – | – |
Positive symptoms | 11.90 ± 5.15 | – | – | – |
Negative symptoms | 23.25 ± 8.50 | – | – | – |
General psychopathology | 25.66 ± 6.02 | – | – | – |
ApoA1 level (g/L) | 1.53 ± 0.38 | – | – | – |
ApoB level (g/L) | 0.89 ± 0.24 | – | – | – |
ApoA1/ApoB | 1.82 ± 0.62 | – | – | – |